Global law firm White & Case LLP has advised FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital, on its business combination with Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company, which is developing PBI-0451 as a novel direct-acting, oral antiviral drug candidate designed to treat SARS-CoV-2 infections. The combined company, which is renamed Pardes Biosciences, Inc., commenced trading its shares Monday, December 27 on the Nasdaq Global Market under the symbol "PRDS."
The White & Case team that advised on the transaction was led by partners Joel Rubinstein and Bryan Luchs, and included counsel Patti Marks and Jessie Baxter, and associate Solange Etessami in New York, and associates Gabrielle Hodgson and Sarah Phillips in Silicon Valley. The team was assisted by partner Sang Ji and associate Mitchell Li (Tax), and partner Victoria Rosamond (Employment, Compensation & Benefits) in New York.
White & Case also previously advised FS Development Corp., the first SPAC sponsored by Foresite Capital, in its business combination with Gemini Therapeutics, which closed in February 2021.
For more information please speak to your local media contact.